Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
history and physical examination, such as digital rectal examination, faecal occult blood test (FOBT), complete blood profile (blood count, transaminases, lactic dehydrogenase, LDH), and carcino-embryonic antigen (CEA) test. Technical tests included, depending on tumour entity, abdominal ultrasound, chest radiography (CXR), colonoscopy, CT of the pelvis, and rigid procto-rectoscopy. The follow-up programmes stopped in cases of cancer recurrence, severe other diseases, patient death, or on patients (...) in colorectalcancer: cost-effectiveness analysis of established and novel concepts. Langenbeck's Archiv fur Chirugie 2000; 385(6): 412-420 Indexing Status Subject indexing assigned by NLM MeSH Carcinoembryonic Antigen /blood; ColonicNeoplasms /prevention & Colonoscopy /economics; Continuity of Patient Care /economics; Cost-Benefit Analysis; Female; Germany; Humans; Male; Neoplasm Recurrence, Local /prevention & Occult Blood; Randomized Controlled Trials as Topic; Rectal Neoplasms /prevention & Tomography
Cost-effectiveness analysis of immunochemical occult blood screening for colorectalcancer among three fecal sampling methods Cost-effectiveness analysis of immunochemical occult blood screening for colorectalcancer among three fecal sampling methods Cost-effectiveness analysis of immunochemical occult blood screening for colorectalcancer among three fecal sampling methods Yamamoto M, Nakama H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Immunochemical occult blood screening for colorectalcancer using three different fecal sampling methods followed by a diagnostic examination (colonoscopy) for positive test results. Each participant provided fecal samples on three consecutive days. The first screening method
of colonoscopy in screening for colorectalcancer. Annals of Internal Medicine 2000; 133(8): 647-649 PubMedID Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Colonoscopy /economics; ColorectalNeoplasms /prevention & Cost-Benefit Analysis; Humans; Mass Screening /economics /methods; Occult Blood; Risk Factors; Sigmoidoscopy /economics; control /therapy AccessionNumber 22000008329 Date bibliographic record published 31/12/2002 Date abstract record published 31/12/2002 NHS Economic (...) Cost-effectiveness of colonoscopy in screening for colorectalcancer Cost-effectiveness of colonoscopy in screening for colorectalcancer Cost-effectiveness of colonoscopy in screening for colorectalcancer Sonnenberg A, Delco F, Inadomi J M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment
selectively. Implications of the study The authors noted that, although cost-effective, the screening programme offered a limited effectiveness. Consequently, further research should focus on more effective, non-invasive screening tools for the detection of colorectalcancer, such as blood and stool tumour markers or new imaging technologies. Finally, the authors pointed out that compliance with screening represented a crucial variable in the analysis. Source of funding Supported in part by an American (...) Digestive Health Foundation Outcomes Research Training Award; NIH, grant numbers PE14001, DK07634 and DK34987. Bibliographic details Helm J F, Russo M W, Biddle A K, Simpson K N, Ransohoff D F, Sandler R S. Effectiveness and economic impact of screening for colorectalcancer by mass faecal occult blood testing. American Journal of Gastroenterology 2000; 95(11): 3250-3258 PubMedID DOI Original Paper URL D&_user=126317&_coverDate=11%2F30%2F2000&_rdoc=40&_fmt=summary&_orig=bro wse&_srch=%23toc%236076
assigned by NLM MeSH Adenocarcinoma /diagnosis /drug therapy /economics /mortality /secondary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols /economics; Camptothecin /administration & ColorectalNeoplasms /diagnosis /drug therapy /economics /mortality; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Administration Schedule; Female; Fluorouracil /administration & France; Health Care Costs; Hospital Costs; Humans; Infusions, Intravenous; Male; Middle Aged; Salvage Therapy; Sensitivity (...) Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectalcancer Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectalcancer Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectalcancer Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P Record Status This is a critical abstract of an economic
of the National Cancer Institute 1995;87:417-426. Indexing Status Subject indexing assigned by NLM MeSH Colonic Polyps /prevention & Colonoscopy /economics; ColorectalNeoplasms /economics /epidemiology /prevention & Cost-Benefit Analysis; Humans; Life Expectancy; Life Tables; Male; Markov Chains; Mass Screening /economics /methods; Middle Aged; Occult Blood; Patient Compliance; Risk Factors; Sigmoidoscopy /economics; control; control AccessionNumber 22000008306 Date bibliographic record published 31/10/2003 (...) that allowed for the detection and treatment of cancer. Outcomes assessed in the review All of the following commenced at age 55 and formed the input parameters to the model. Repeated events continued until 85. The prevalence of polyps at age 50 (PP50) and its distribution between distal (DP50) and high-risk polyps (HRP50). Annual transition probabilities (ATP) between stages in the colorectaldisease history. CRC diagnosis probabilities (CRCDP) due to symptoms. Annual CRC specific mortality rates (ACRCMR
of Cancer 2000; 36(5): 647-650 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Colonoscopy /methods; ColorectalNeoplasms /diagnosis /economics; Cost-Benefit Analysis; False Negative Reactions; False Positive Reactions; Humans; Immunologic Techniques /economics /statistics & Middle Aged; Occult Blood; Sensitivity and Specificity; Specimen Handling; numerical data AccessionNumber 22000000910 Date bibliographic record published 28/02/2001 Date abstract record published 28/02 (...) A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectalcancer A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectalcancer A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectalcancer Nakama H, Zhang B, Fattah A S Record Status This is a critical abstract
conclusions As a single diagnostic imaging method, LAP-LUS had the highest sensitivity followed by EUS, but the combination of EUS and LAP-LUS detected the highest number of patients with nonresectable disease. Although LAP had a tendency to provide more information in patients with gastric cancer, the results demonstrated no significant difference between the imaging methods when they were stratified according to the type of tumour. Modelling A simple model was used to evaluate the cost-effectiveness (...) Cost-effectiveness of different diagnostic strategies in patients with nonresectable upper gastrointestinal tract malignancies Cost-effectiveness of different diagnostic strategies in patients with nonresectable upper gastrointestinal tract malignancies Cost-effectiveness of different diagnostic strategies in patients with nonresectable upper gastrointestinal tract malignancies Mortensen M B, Ainsworth A P, Langkilde L K, Scheel-Hincke J D, Pless T, Hovendal C Record Status This is a critical
, diagnosis and treatment of colorectalneoplasms in order to determine the cost-effectiveness of different age dependent screening strategies. Separate male and female models were constructed due to gender differences in natural life expectancy and colorectalneoplasia incidence. The structure and workings of the model were very well described within the paper and justified by reference to relevant literature. Outcomes assessed in the review The review assessed the following outcomes: Colonoscopic (...) sensitivity to detect: CRC, Large polyps (larger than 1cm), intermediate polyps (6-9mm), small polyps smaller than 5mm). Colonoscopic complication rates for: postpolypectomy haemorrhage, perforation, mortality and utilities. The natural history of colorectalneoplasia was identified using relevant literature and used to inform the model. Study designs and other criteria for inclusion in the review Not stated. Sources searched to identify primary studies Not stated. Criteria used to ensure the validity
that early detection offers their patients. The authors also highlighted the need for further research in the form of large-scale prospective studies to provide a stronger basis for developing a preventive strategy. Source of funding Supported by the Spanish Association against Cancer and the Castillian Association of the Digestive System. Bibliographic details Lopez P J, Nieto E M, Rodriguez A C, Molinero M J, Olmo D G, Albero J S. Economic evaluation of colorectalcancer screening with faecal occult (...) Economic evaluation of colorectalcancer screening with faecal occult blood detection Economic evaluation of colorectalcancer screening with faecal occult blood detection Economic evaluation of colorectalcancer screening with faecal occult blood detection Lopez P J, Nieto E M, Rodriguez A C, Molinero M J, Olmo D G, Albero J S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary
Active specific immunotherapy for stage II and stage III human coloncancer: a randomised trial. Coloncancer is curable by surgery, but cure rate depends on the extent of disease. We investigated whether adjuvant active specific immunotherapy (ASI) with an autologous tumour cell-BCG vaccine with surgical resection was more beneficial than resection alone in stage II and III colon cancer.In a prospective randomised trial, 254 patients with coloncancer were randomly assigned postoperative ASI (...) ) and there was a trend towards improved overall survival.ASI gave significant clinical benefit in surgically resected patients with stage II coloncancer. ASI has minimal adverse reactions and should be considered in the management of stage II coloncancer.
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. We have shown previously that lumpectomy with radiation therapy was more effective than lumpectomy alone for the treatment of ductal carcinoma in situ (DCIS). We did a double-blind randomised controlled trial to find out whether lumpectomy, radiation therapy, and tamoxifen was of more benefit than lumpectomy and radiation therapy alone for DCIS.1804 women (...) with DCIS, including those whose resected sample margins were involved with tumour, were randomly assigned lumpectomy, radiation therapy (50 Gy), and placebo (n=902), or lumpectomy, radiation therapy, and tamoxifen (20 mg daily for 5 years, n=902). Median follow-up was 74 months (range 57-93). We compared annual event rates and cumulative probability of invasive or non-invasive ipsilateral and contralateral tumours over 5 years.Women in the tamoxifen group had fewer breast-cancer events at 5 years than
1999LancetControlled trial quality: predicted high
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectalcancer. Two years after undergoing resection of liver metastases from colorectalcancer, about 65 percent of patients are alive and 25 percent are free of detectable disease. We tried to improve these outcomes by treating patients with hepatic arterial infusion of floxuridine plus systemic fluorouracil after liver resection.We randomly assigned 156 patients at the time of resection of hepatic (...) metastases from colorectalcancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone. Patients were stratified according to previous treatment and the number of liver metastases identified at operation. The study end points were overall survival, survival without recurrence of hepatic metastases, and survival without any metastases at two years.The actuarial rate
patients. The number of LYG with liver resection under this scenario would be 1.5, and the cost per LYG would be 3,945. Authors' conclusions Liver resection seemed to produce survival advantages for patients with colorectalcancer and liver metastases, provided that the surgery rendered the patient tumour free and patients did not have extrahepatic disease. For patients with multiple liver secondaries, the prognosis was worst but they experienced a survival advantage from resection, provided they did (...) :59-71. Wade TP, Virgo KS, Li MJ, et al. Outcomes after detection of metastatic carcinoma of the colon and rectum in a national hospital system. Journal of the American College of Surgeons 1996;182:353-61. Wagner JS, Adson MA, van Heerden JA, et al. The natural history of hepatic metastases from colorectalcancer. A comparison with resective treatment. Annals of Surgery 1984;199:502-8. Indexing Status Subject indexing assigned by NLM MeSH Analysis of Variance; Antineoplastic Agents /economics
. Project page URL Indexing Status Subject indexing assigned by CRD MeSH ColorectalNeoplasms; GastrointestinalDiseases; Mass Screening; Neoplasms; Occult Blood Language Published English, French Country of organisation Canada Province or state Quebec Address for correspondence 2021, avenue Union, #1040, Montreal, Quebec H3A S29, Canada. Tel: +1 514 873 2563;Fax: +1 514 873 1369 Email: email@example.com AccessionNumber 31999009151 Date bibliographic record published 24/07/2000 Date abstract (...) ). CETS 99-2 RE. 1999 Authors' objectives This report aims to review the epidemiology and carcinogenesis of colorectalcancer, then examine the evidence regarding the efficacy of different screening strategies both for precancerous lesions and malignant lesions that are still in their early stages. Authors' conclusions CETS believes that a colorectalcancer screening program would lead to a significant reduction in the mortality due to this type of cancer. Such a program would target asymptomatic
Irinotecan as second line chemotherapy in colorectalcancer Irinotecan as second line chemotherapy in colorectalcancer Irinotecan as second line chemotherapy in colorectalcancer Smithies A, Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smithies A, Stein K. Irinotecan as second line chemotherapy in colorectalcancer (...) . Southampton: Wessex Institute for Health Research and Development (WIHRD) 1999 Authors' objectives To assess the effectiveness and cost-effectiveness of irinotecan as second line chemotherapy in colorectalcancer Authors' conclusions Irinotecan is a promising new agent which appears to produce small survival gains among people with advanced colorectalcancer. The evidence in its support comes from two phase III randomised controlled trials, both of which, have some methodological problems. The Committee
COX-2 inhibitors: a role in colorectalcancer? COX-2 inhibitors: a role in colorectalcancer? COX-2 inhibitors: a role in colorectalcancer? Otten N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Otten N. COX-2 inhibitors: a role in colorectalcancer? Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien (...) de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 1999: 4 Authors' objectives To summarise the available evidence on the use of COX-2 inhibitors in the treatment or prevention of colorectalcancer. Authors' conclusions The use of ASA or NSAIDs is not recommended for the prevention of colorectalcancer as there is insufficient high quality evidence of its benefit despite numerous epidemiological and laboratory studies. Project page URL Indexing Status Subject indexing assigned
. Bibliographic details Beard S M, Holmes M, Majeed A, Price C. Hepactic resection as a treatment for liver metastases in colorectalcancer. Sheffield: University of Sheffield, Trent Institute for Health Services Research. Guidance Notes for Purchasers; 99/02. 1999 Indexing Status Subject indexing assigned by CRD MeSH ColonicNeoplasms; Hepatectomy; Liver Neoplasms /surgery AccessionNumber 12000008029 Date bibliographic record published 31/10/2000 Date abstract record published 31/10/2000 Record Status (...) -hepatectomy. Participants included in the review People with liver metastases related to primary colorectalcancer. Mean age at operation was around 60 years and similar numbers of men and women were studied. Outcomes assessed in the review Overall survival, disease-free survival, operative morbidity, operative mortality and/ or pre-operative prognostic factors. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected for the review, or how many
examined different patients, thus, the proportion of patients with polyps detected by each type of endoscopist cannot be directly compared. The strengths of this study include the large sample size, prospective data collection and the fact that it was conducted as part of an institutional colorectalcancer screening programme. Validity of estimate of costs Only direct costs were considered. Indirect costs falling to the patients were not included. Costs were derived from a local source and, hence (...) Screening for colorectalcancer with flexible sigmoidoscopy by nonphysician endoscopists Screening for colorectalcancer with flexible sigmoidoscopy by nonphysician endoscopists Screening for colorectalcancer with flexible sigmoidoscopy by nonphysician endoscopists Wallace M B, Kemp J A, Meyer F, Horton K, Reffel A, Christiansen C L, Farraye F A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief